Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 16,401 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Central Nervous System Disorder Clear all

Conditions: Traumatic Brain Injury
Interventions: Brain Training Program 1, Brain Training Program 2; Behavioral
Lead sponsor: The University of Texas at Dallas; Other
Eligibility: 19 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Essential Tremor, Tremor
Interventions: Ethanol, Propranolol; Other · Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 21 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Acute Stroke
Interventions: Rehabilitation Therapy on Experimental Robotic Table and standard of care, Rehabilitation Therapy as part of Standard of Care (Control); Device · Genetic
Lead sponsor: Bright Cloud International Corp; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: North Brunswick, New Jersey • West Orange, New Jersey

Conditions: Migraine With or Without Aura
Interventions: Naltrexone and Acetaminophen, Naltrexone and Acetaminophen-High Dose, Naltrexone Alone (regular dose), Acetaminophen Alone, Matching Placebo; Drug
Lead sponsor: Allodynic Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: North Miami, Florida

Conditions: Stroke, Aphasia, Reading Disorder
Interventions: Phono-Motor Therapy, Aerobic Exercise Training (AET), Stretching; Behavioral
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 85 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Epilepsy
Interventions: Discontinue antiseizure medications; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Dementia, Alzheimer's Disease, Frontotemporal Dementia
Interventions: In-home technology, Limited in-home technology; Device
Lead sponsor: University of California, Berkeley; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 5
States / cities: Berkeley, California • Los Angeles, California • Orange, California + 2 more

Conditions: Multiple Sclerosis
Interventions: Rolipram; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alzheimer Disease, Dementia, Mild, Mild Cognitive Impairment
Interventions: Digital - Google Calendar, Paper-based - Memory Support System; Behavioral
Lead sponsor: Baylor University; Other
Eligibility: 50 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Austin, Texas • Temple, Texas • Waco, Texas

Conditions: Multiple Sclerosis, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Demyelinating Diseases, Autoimmune Diseases, Immune System Diseases, Pathologic Processes
Interventions: Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test, T-Detect COVID T-cell blood test; Device
Lead sponsor: Dragonfly Research, LLC; Other
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Wellesley, Massachusetts

Conditions: Cushing Disease
Interventions: Pasireotide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 3
States / cities: Boston, Massachusetts • Portland, Oregon • Philadelphia, Pennsylvania

Conditions: Intracranial Hemorrhage
Interventions: Use of fixed-dosed 4F-PCC; Procedure
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years to 75 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Focal Dystonia
Interventions: Acetyl-Hexapeptide Topical Treatment, placebo; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cerebrovascular Accident
Interventions: Fast Walking with Fast Functional Electrical Stimulation (FES) Training, Fast Walking; Device · Other
Lead sponsor: Emory University; Other
Eligibility: 30 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Adult Spinal Deformity
Interventions: Interventions; Procedure
Lead sponsor: AO Foundation, AO Spine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 5
States / cities: San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 2 more

Conditions: Cervicogenic Headache, Neck Pain, Whiplash, Kyphotic and Reversed Cervical Curves
Interventions: Not listed
Lead sponsor: Logan College of Chiropractic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Chesterfield, Missouri

Conditions: PD - Parkinson's Disease
Interventions: Medtronic Percept Deep Brain Stimulation (cDBS), Medtronic Percept Deep Brain Stimulation (daytime aDBS), Medtronic Percept Deep Brain Stimulation (nighttime aDBS); Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Spinal Muscular Atrophy
Interventions: nusinersen; Drug
Lead sponsor: Biogen; Industry
Eligibility: 2 Years to 14 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York • Dallas, Texas + 1 more

Conditions: Anxiety Disorder, Seizures, Epilepsy, Partial Epilepsy, Depression
Interventions: Buspirone, Placebo; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Stroke
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Alzheimer Disease
Interventions: GSI-953, Placebo; Drug · Other
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Glendale, California

Conditions: Fabry Disease
Interventions: migalastat hydrochloride, Placebo; Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 16 Years to 74 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Decatur, Georgia + 10 more

Conditions: Urea Cycle Disorders
Interventions: Not listed
Lead sponsor: Mark Batshaw; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Cerebral Adrenoleukodystrophy (CALD)
Interventions: Lenti-D Drug Product (eli-cel); Genetic
Lead sponsor: Genetix Biotherapeutics Inc.; Industry
Eligibility: Up to 17 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 3
States / cities: Los Angeles, California • Boston, Massachusetts • Minneapolis, Minnesota

Search by objective public record fields.

Brain Training to Enhance Frontal Lobe Reasoning

Functional Imaging of Tremor Circuits and Mechanisms of Treatment Response

Arm Motor Rehabilitation, Entertainment and Cognition System for the Elderly (Clinical Trial)

An Acute Migraine Factorial Study

Combined Exercise and Targeted Therapy for Post-Stroke Reading Deficits

Outcomes After Planned Discontinuation of AntiSeizure Medication

In-Home Technology for Dementia Caregivers

Rolipram to Treat Multiple Sclerosis

Paper-Based and Smartphone-Based Memory Supports

Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab

Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease

Evaluation of 4-Factor PCC in DOAC-associated Intracranial Hemorrhage

A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm

Stroke Gait Rehabilitation Using Functional Electrical Stimulation

Neurologic Complications in Spinal Deformity Surgery - Extension

Multi Cervical Unit Measures of Cervical Isometric Strength and Range of Motion: A Pilot Study

Simplified, Scalable, 24-hour Adaptive DBS in Parkinson's Disease

An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)

Buspirone Therapy for Localized Epilepsy

Factor XI Levels in Acute Ischemic Stroke

Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients

Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders

A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)